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Abstract
Bariatric surgery affects gut microbial flora due to the anatomical and physiological changes it causes in the gastrointestinal 
tract. Understanding the interaction between the gut flora, the type of bariatric surgery and weight loss may help improve 
bariatric surgery outcomes. This study was designed to compare the effects of Roux-en-Y Gastric Bypass (RYGB) and Sleeve 
Gastrectomy (SG) on two main phyla of the gut microbiota in humans and evaluate their potential effect on weight changes. 
Thirty morbidly obese patients were divided into two groups and underwent laparoscopic SG or laparoscopic RYGB. The 
patients’ weight changes and fecal samples were evaluated at baseline and 6 months after the surgery. A microbial flora 
count was carried out of the phyla Bacteroidetes and Firmicutes and Bacteroides Fragilis. Changes in the abundance of the 
flora and their correlation with weight loss were analyzed. After 6 months, the patients with a history of RYGB showed a 
significant decrease in stool Bacteroidetes while the reduction in the SG group was insignificant. Firmicutes abundance was 
almost unchanged following SG and RYGB. There was no significant change in Bacteroides Fragilis abundance in either of 
the two groups, but a positive correlation was observed between Bacteroides Fragilis and weight loss after SG and RYGB. 
Bariatric surgery can affect gut microbiota. It can be concluded that these changes are dependent on many factors and may 
play a role in weight loss.
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Introduction
The number of obese and overweight people has doubled 
across the world since 1980. As of 2014, 52% of adults 
were overweight or obese, and morbid obesity is currently 
a public health problem [1]. Obesity increases the risk of 
life-threatening diseases, including type-2 diabetes, arte-
rial hypertension, coronary heart disease, and cancer [2]. 
Although physical inactivity and inappropriate eating habits 
play a role in weight gain, studies suggest that genes are also 
responsible for obesity [3].
Obesity affects the intestinal microbiota, as well [4, 5]. 
The human gut hosts roughly  1014 microorganisms, which 
contain 2–20 million microbial genes [6]. Most human gut 
microbiota includes four major bacterial phyla: Bacteroi-
detes and Firmicutes, which collectively organize about 60% 
of the digestive tract bacteria [7], Proteobacteria and Act-
inobacteria [6]. In addition, Bifidobacterium, Lactobacillus, 
Bacteroides, Clostridium, Escherichia and Streptococcus are 
the most common gut bacteria in adults.
Gut microbial imbalance (dysbiosis) can be developed 
in a variety of ways, including dietary changes, stress, the 
host genetics, antibiotic consumption and contamination 
with pathogenic bacteria [8], or as a consequence of met-
abolic syndromes (such as obesity, type-2 diabetes, etc.), 
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neurological diseases, allergies, Irritable Bowel Syndrome 
(IBS), and Inflammatory Bowel Disease (IBD) [9].
Bariatric surgery is reported to be the most successful 
treatment for morbid obesity and its related comorbidities. 
In general, bariatric surgery can prevent weight gain by dif-
ferent mechanisms [10]. Roux-en-Y gastric bypass (RYGB) 
is considered the gold standard in bariatric surgery as a 
restrictive-malabsorptive technique that results in excellent 
long-term weight loss and improvement in obesity-related 
comorbidities. The highest number of operations performed 
in the US pertains to Sleeve Gastrectomy (SG) [11] that has 
recently gained popularity because of its safety and simplic-
ity, great results in terms of weight loss and a comorbidity 
improvement comparable to RYGB [12].
Postoperative changes in the gut microbiota are associ-
ated with improvement in metabolic state and remission of 
inflammatory responses after surgery [13], which suggests 
that alterations of the gut microbiota may be one of the 
mechanisms by which bariatric surgery improves metabo-
lism and contributes to long-lasting body weight reduction 
and the resolution of obesity-related comorbidities.
In the literature, changes in gut microbiota following bari-
atric surgery have been evaluated, but controversial results 
are achieved [14–18]. Some studies have shown a decrease 
in the relative abundance of Firmicutes after SG and an 
increase in Bacteroidetes following RYGB [14]. Meanwhile, 
some other studies concluded RYGB leads to an increase in 
Firmicutes phyla, but a decrease in Bacteroidetes phyla, and 
that SG increased Bacteroidetes phyla [15]. However, some 
studies revealed no changes in Firmicutes and Bacteroidetes 
following bariatric surgery [16].
Given the controversial results of these studies, the pre-
sent study compares the effects of RYGB and SG on two 
main phyla of the gut microbiota in humans and evalu-
ates their potential effect on weight changes and examines 
whether postoperative gut microbiota are correlated with 
BMI changes.
Materials and methods
Thirty morbidly obese patients with BMI > 40 were studied 
from February to May 2019 after submitting their consent 
form. At first, demographic data, including age, gender, 
weight, height and BMI, were registered and all the patients 
gave fecal samples. Based on factors such as eating hab-
its, presence and grade of hiatal hernia, comorbidities and 
GERD symptoms, the patients were divided into two groups 
who underwent either laparoscopic sleeve gastrectomy 
(LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB). 
The inclusion criteria for the RYGB group included snack-
ing, medium or large hiatal hernia, type-2 diabetes, GERD 
symptoms and esophagitis grade B or above. The other indi-
viduals underwent SG.
The surgeries were performed by the same surgical team. 
LRYGB entailed the formation of a small gastric pouch 
approximately 6 cm in length and 36 French in diameter 
along the lesser curvature of the stomach, and the jejunum 
was then divided 125 cm distal to the ligament of Treitz. 
End-to-side gastrojejunostomy about 3 cm in diameter using 
a linear stapler was then carried out, followed by a side-to-
side jejunojejunostomy 75 cm distal to the gastrojejunos-
tomy. At last, jejunojejunostomy and Petersen’s defects were 
closed. LSG included the gastrolysis of a greater curvature, 
continued by stapling the stomach from 4 cm by pylorus 
to the His angle beside a 36 French caliber tube. Omen-
topexy was also performed to prevent sleeve twisting. All 
the patients were discharged the next day after the surgery 
with a drug prescription containing Ursodeoxycholic Acid 
(UDCA), 300 mg, twice daily as prophylaxis for gallstone 
formation and Proton Pump Inhibitor (PPI), 40 mg, twice 
daily, for 6 months and multivitamins daily. The follow-up 
visits were performed on the 3rd and 10th days and 1st, 3rd 
and 6th months after surgery. In the postoperative period and 
follow up visits, no complication was detected. Furthermore, 
the patients refrained from using antibiotics or other items 
affecting the gut microbiota during this period.
After 6 months, they were re-examined, their weight was 
measured and fecal samples were taken. The stool specimens 
were transferred to special containers to add DNA and RNA 
stabilizers to them at the university’s microbiology labora-
tory. The samples were stored at − 20 °C (cold chain was 
observed for transferring the samples). The samples were 
extracted using a fecal extraction kit according to the manu-
facturer’s protocol and were stored in a freezer at − 80 °C for 
subsequent testing. The primers required for the microbial 
flora species, including Bacteroidetes phylum, Firmicutes 
phylum and Bacteroides Fragilis, were requested to be syn-
thesized by the primer synthesis company and were kept 
at − 20 °C for further testing.
The experiments were performed by Reverse Transcrip-
tion Polymerase Chain Reaction (RT-PCR) at the micro-
biology department of the university and the results were 
recorded.
Statistical analysis
Data were presented as mean and standard deviation (SD) 
for the continuous variables and as percentages for the 
categorical variables. The Kolmogorov–Smirnov test was 
used before performing further analyses, and log transfor-
mation was used for the variables with a significant devia-
tion from the normal distribution. A Chi-square (χ2) test 
was used for comparing the categorical data between the 
two groups. A paired-sample t test or Wilcoxon’s test was 
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used to calculate the changes within the groups 6 months 
after surgery. Mann–Whitney’s U test was used to calculate 
the differences and changes from the baseline between the 
groups for the continuous data. Spearman’s correlation test 
was used to demonstrate correlations. All the statistical tests 
were performed in SPSS-17 (SPSS Inc., Chicago, IL, USA) 
with the 0.05 significance level.
Results
Thirty morbidly obese patients who were candidates for 
bariatric surgery were enrolled in this study. Twenty-three 
patients (76.7%) were female. The mean ± standard devia-
tion (SD) of age was 37 ± 9.73 (range 18–62 years) and the 
mean ± SD of BMI was 44.61 ± 3.77 (range 38.21–51.20 kg/
m2). Eighteen (60%) of the patients underwent sleeve gas-
trectomy (SG group) and 12 (40%) Roux-en-Y gastric bypass 
(RYGB group). As shown in Table 1, the groups were simi-
lar at baseline in terms of characteristics such as age, gender, 
BMI, Bacteroidetes phylum, Firmicutes phylum and Bacte-
roides Fragilis. Table 1 presents the baseline characteristics 
of both groups.
Post‑operative analysis
Six months after the surgery, the mean ± SD of excess weight 
loss (EWL%) was 57.72 ± 15.08%. The type of bariatric sur-
gery (P = 0.371), gender (P = 0.163), and age (P = 0.164) had 
no significant effect on EWL.
Table 2 shows the changes in the measured characteristics 
at baseline and 6 months after the surgery between the SG 
and RYGB groups and within each group.
At this time, BMI reduced significantly in the SG and 
RYGB groups (P < 0.001 for both groups); the between-
group analysis revealed that BMI reduction did not differ 
Table 1  The baseline 
characteristics between the 
two different bariatric surgery 
groups
SG Sleeve Gastrectomy, RYBG Roux-en-Y Bypass Gastrectomy, BMI Body Mass Index, IQR Inter Quartile 






1 37 ± 10.81 37 ± 9.27 Age, mean ± SD, years
0.669 10 (83.3%) 13 (72.2%) Females, no. (percent)
0.560 122.62 ± 15.92 119.07 ± 16.26 Weight, mean ± SD, kg
0.188 45.73 ± 3.94 43.87 ± 3.56 BMI, mean ± SD, kg/m2
0.961 9.62 ± 0.59 9.63 ± 0.6 Bacteroidetes phylum, mean ± SD
0.884 8.12 ± 0.69 8.05 ± 0.8 Firmicutes phylum, mean ± SD
0.950 0.03 (0.004, 0.1) 0.02 (0.01, 0.08) Firmicutes/Bacteroidetes ratio, median (IQR)
0.091 5.25 ± 1.31 6.24 ± 1.77 B Fragilis, mean ± SD
Table 2  The changes in the measured characteristics from baseline to 6 months after the surgery
BMI Body Mass Index, EWL Excess Weight Loss, SG Sleeve Gastrectomy, RYBG Roux-en-Y Bypass Gastrectomy, IQR Inter Quartile Range, 
SD Standard Deviation
a Compared with SG group, P > 0.05
*Compared with preoperative, P value < 0.05
§ Compared with preoperative, P value < 0.01
Variables SG group (N = 18) RYGB group (N = 12) Total (N = 30)
Pre-op Post-op Pre-op Post-op Pre-op Post-op
BMI, Mean ± SD, kg/m2 43.87 ± 3.56 32.59 ± 3.29§ 45.73 ± 3.94a 34.65 ± 4.71a§ 44.61 ± 3.77 33.41 ± 3.98§
Weight, mean ± SD, kg 119.07 ± 16.26 88.82 ± 11.70§ 122.62 ± 15.92a 93.28 ± 15.36a§ 120.49 ± 15.94 90.60 ± 13.22§
EWL%, mean ± SD, kg – 59.77 ± 13.47 – 54.65 ± 17.38a 57.72 ± 15.08
Bacteroidetes phylum, 
mean ± SD
9.63 ± 0.60 9.28 ± 0.58 9.62 ± 0.59a 8.76 ± 0.93* 9.62 ± 0.59 9.07 ± 0.77§
Firmicutes phylum, mean ± SD 8.05 ± 0.8 8.28 ± 0.82 8.12 ± 0.69a 7.83 ± 0.82 8.07 ± 0.74 8.10 ± 0.84
Firmicutes/Bacteroidetes ratio, 
median (IQR)
0.02 (0.01, 0.08) 0.09 (0.03, 0.32) 0.03 (0.01, 0.1)a 0.06 (0.03, 0.66) 0.03 (0.01, 0.08) 0.07 (0.03, 0.391)*
B Fragilis, mean ± SD 6.24 ± 1.77 6.86 ± 1.66 5.25 ± 1.31a 6.15 ± 2.60 5.84 ± 1.66 6.58 ± 2.08
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significantly between the SG and RYGB groups (P = 0.168). 
The same result was obtained for weight reduction 
(P = 0.765) and EWL% (P = 0.371).
Firmicutes phylum, Bacteroidetes phylum, 
Firmicutes/Bacteroidetes ratio and B Fragilis 6 
months after the surgery
As shown in Table 2, the patients who underwent RYGB had 
a significant reduction in their Bacteroidetes count compared 
to pre-surgery (P = 0.024), but this reduction was not signifi-
cant in the SG group (P = 0.071), and changes in the Firmi-
cutes count compared to pre-surgery were not significant in 
either the SG (P = 0.329) or RYGB (P = 0.407) groups.
The Firmicutes to Bacteroidetes ratio was not signifi-
cantly different from the baseline in the SG (P = 0.145) or 
RYGB (P = 0.06) groups. Also, after surgery, this change 
was not significantly different between the two groups 
(Table 2, P = 0.687).
The B Fragilis count did not differ significantly between 
the baseline and 6 months post-surgery in the SG and RYGB 
groups or between the two groups (P > 0.05 for all). With-
out considering the type of bariatric surgery, the analysis 
revealed a significant overall reduction in the Bacteroidetes 
count (P < 0.01) and a significant increase in the Firmicutes 
to Bacteroidetes ratio (Table 2, P = 0.037).
The correlation between the Bacteroidetes 
and Firmicutes counts 
and the Firmicutes/Bacteroidetes ratio and B Fragilis 
count with age, BMI and EWL%
There were no significant correlations for the pre-operative 
Bacteroidetes, Firmicutes, Firmicutes/Bacteroidetes ratio 
and B Fragilis with age, pre-op BMI and EWL% (P > 0.05 
for all; Table 3).
Six months after the surgery, a significant negative cor-
relation was observed between the B Fragilis count and post-
op BMI in the RYGB subgroup (P = 0.035; r = − 0.612) and 
a significant positive correlation was observed between the 
B Fragilis count and EWL% in the SG group (P = 0.028; 
r = 0.518; Table 4).
Discussion
While bariatric surgery is the most effective treatment for 
morbid obesity, there is a lot remaining to understand about 
it. Previous studies have demonstrated alterations in gut 
Table 3  Correlation of age, 
pre-op BMI and EWL% 
with pre-op count of 
Bacteroidetes, Firmicutes, 
Firmicutes/Bacteroidetes ratio 







Pre-op Bacteroidetes 0.202 (r = − 0.240) 0.612 (r = 0.097) 0.147 (r = 0.271)




0.149 (r = 0.270) 0.353 (r = − 0.176) 0.457 (r = − 0.141)
Pre-op B Fragilis 0.152 (r = − 0.268) 0.283 (r = − 0.203) 0.201 (r = 0.240)
Table 4  Correlation of age, 
post-op BMI, EWL% with 
post-op count of Bacteroidetes, 
Firmicutes, Firmicutes / 
Bacteroidetes ratio and B 








 SG group 0.354 (r = 0.232) 0.359 (r = − 0.320) 0.288 (r = 0.265)
 RYGB group 0.958 (r = − 0. 017) 0.100 (r = 0.497) 0.329 (r = − 0.308)
Post-op Firmicutes
 SG group 0.293 (r = 0.262) 0.903 (r = 0.031) 0.647 (r = − 0.116)




 SG group 0.671 (r = 0.108) 0.295 (r = 0.261) 0.138 (r = − 0.363)
 RYGB group 0.551 (r = 0.192) 0.863 (r = − 0.056) 0.820 (r = 0.074)
Post-op B Fragilis
 SG group 0.131 (r = − 0.370) 0.074 (r = − 0.431) 0.028 (r = 0.518)
 RYGB group 0.955 (r = 0.018) 0.035 (r = − 0.612) 0.153 (r = 0.439)
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microbiota associated with bariatric surgery and a relation-
ship between altered microbiota and metabolic features; 
however, various mechanisms are at play in bariatric surgery 
outcomes that should be investigated [18].
The gut microbiota plays a critical role in human health in 
that bacteria produce enzymes for carbohydrate metabolism, 
short-chain fatty acids, lipopolysaccharides and secondary 
bile acids [5] which enter the circulatory system to influence 
inflammation, immunity, energy homeostasis, and intestinal 
transit regulation [7].
Changes in the gut microbiota have been shown to be cor-
related with some metabolic factors such as BMI, fat mass, 
calorie intake, satiety hormones and appetite [14]. Another 
study further demonstrated that altered gut microbiota after 
RYGB contribute to a reduction in the host’s body weight 
and adiposity, and the transfer of post-RYGB gut microbiota 
to germ-free mice also resulted in lost body weight [19].
The gut microbiota composition has been shown to differ 
significantly between obese and lean people, with a higher 
ratio of Firmicutes to Bacteroidetes in the obese [20]. The 
gut microbiota of obese people has a lower bacterial variety 
compared to that in lean individuals [21].
One systematic review showed that the majority of stud-
ies have found a decrease in the abundance of Firmicutes and 
an increase in Bacteroidetes following bariatric surgery [14]. 
Nonetheless, one study revealed higher Firmicutes after both 
RYGB and SG in relation to the pre-operative levels [15]. 
Gastric bypass has also been shown to reduce Bacteroidetes 
and Bacteroides counts [16].
A clinical study revealed that SG can lead to obvious 
changes in the metabolic properties of obese patients, per-
haps due to the shifts in gut microbiota [17]. Likewise, 
another study reported permanent changes in the composi-
tion of the gut microbiota after SG, including an increase in 
Bacteroidetes and a decline in Firmicutes. They also showed 
correlations between some bacterial families and metabolic 
improvements after SG [18]. According to these different 
results, this study was designed to compare the effects of 
RYGB and SG on two main phyla of the gut microbiota.
The present study examined 30 morbidly obese patients 
with a mean BMI of 44.61 kg/m2 and a mean age of 37 years 
who underwent SG and RYGB. Following surgery, at the 6th 
month’s post-operation visit, Bacteroidetes phylum, Firmi-
cutes phylum and Bacteroides Fragilis counts were evalu-
ated in the stool specimens. At baseline, the demographic 
data and microbiota phyla counts were not significantly dif-
ferent between the SG and RYGB groups.
Six months after surgery, the mean EWL% was 
57.72 ± 15.08%, independent of gender and age; also, 
there was no significant difference between the SG and 
RYGB groups in EWL%. The patients who had undergone 
RYGB encountered a decrease in stool Bacteroidetes after 
6 months, which could have been caused by pH reduction 
after bariatric surgery. The same was reported in the study 
by Murphy et al. [15]. The present findings also showed a 
non-significant reduction in Bacteroidetes count in the SG 
group, which is in contrast with the findings reported by 
Davis et al. [14]. Medina et al. also revealed that Firmicutes 
abundance was almost unchanged following SG and RYGB, 
as consistent with the present study [22].
As previously reported, these changes may be due to diet, 
changes in acid exposure after different surgical procedures 
and the consumption of drugs such as PPIs [23]. Medina 
et al., however, found that various changes in microbiota 
lead to an increase in the Bacteroides/Firmicutes ratio in 
patients with a history of SG but a significant decrease in 
the RYGB group [22]. This finding is in contrast with the 
present study finding, as the patients in this study did not 
show any significant changes in the Bacteroides/Firmicutes 
ratio after surgery in either SG or RYGB groups.
According to the present findings, there was no signifi-
cant change in Bacteroides Fragilis abundance between the 
pre-operation and post-operation stool samples. Meanwhile, 
Fernanda et al. detected a decrease in Bacteroides abundance 
in connection with increased serum bilirubin after SG and 
RYGB [24]. The data in the present study did not show any 
significant correlations for the pre-op microbiota phyla with 
age and pre-op BMI, and EWL% did not have a correlation 
with the gut microbiota count either; it can thus be con-
cluded that the pre-op gut microbiota components do not 
have an effect on weight changes following bariatric surgery.
This study did not find any correlations for age, post-op 
BMI, and EWL% with the post-op count of Bacteroidetes 
and Firmicutes and the Firmicutes/Bacteroidetes ratio in 
the two groups, which demonstrates that weight changes 
after SG and RYGB are independent of post-operation Fir-
micutes and Bacteroidetes abundance, which is in line with 
the results of previous studies [22].
Six months after the surgery, a negative correlation was 
found between BMI and the B Fragilis count in the RYGB 
group and a positive correlation between the B Fragilis 
count and EWL% in the SG group, showing the potential 
effect of B Fragilis on weight loss. The present findings are 
in agreement with those reported by Santacruz A. et al., 
which demonstrated a positive correlation between Bacte-
roides Fragilis changes and weight loss after lifestyle modi-
fication by calorie intake restriction and increased exercise. 
These researchers also explained that B Fragilis changes 
are strongly dependent on diet, especially carbohydrate con-
sumption [25]. This is related to the aim of designing this 
study; we did not find any evidence in the literature of the 
relationship of B Fragilis changes with weight loss following 
bariatric surgery.
There is an ongoing debate about these correlations 
because the cause and effect relationship between gut micro-
biota changes and weight changes is not clearly defined yet, 
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although one study reported weight gain in a healthy human 
after fecal microbiota transplantation from another over-
weight human [26]. Likewise, some studies revealed that 
fecal microbiota transplantation (FMT) from lean healthy 
people can lead to weight loss in morbid obese patients [6, 
27, 28].
It should be noted that gut microbiota changes are mul-
tifactorial, depending on geographic area, economic status, 
diet and calorie intake. According to the present findings, 
gut microbiota change patterns following bariatric surgery 
were in contrast with most of the previous studies, which can 
be a result of the differences in race and nutritional patterns. 
Stool sampling also demonstrates mostly large intestine 
microbe changes, and assessing the upper intestinal parts 
for microbe changes is difficult [22].
The most important limitations of this study were small 
sample size and basal characteristic differences in patients. 
Further evaluations should be carried out with a greater 
sample size to compare the groups according to race, diet 
and nutritional patterns. Other less-noticed bacterial species 
should also be examined in future studies.
Conclusion
To conclude, bariatric surgeries can affect gut microbiota 
and change it by unknown mechanisms. Previous studies 
have demonstrated various results and changes in gut micro-
biota after bariatric surgery. These changes which depend 
on many factors may have a role in weight loss. Based 
on the researchers’ best knowledge, this study is the first 
report in humans that shows a positive correlation between 
Bacteroides Fragilis and weight loss after SG and RYGB; 
therefore, fecal microbiota transplantation in obese patients 
containing B Fragilis or probiotics consisting of B Fragilis 
bacteria may accelerate and amplify weight loss after bari-
atric surgical procedures. However, further studies should 
be performed to find more specific and effective microbiota 
for weight loss in morbid obese patients.
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